Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen

Robert P. Kustra, Kimford J. Meador, Bradley K. Evans, Lisa M. Leschek-Gelman, Dawn A. Groenke, Anne E. Hammer, Kevin P. Nanry, John A. Messenheimer, Bassel Abou-Khalil, Sami Aboumatar, Aaron Allen, Avraham Alomzlino, Gregory Anderson, Clara Applegate, Jan Baxt, Beverly Beadle, Peter Bellafiore, Rukmaiah Bhupalam, Harvinder Birk, Susan BlueAlphonse Bobowick, Bruce Bogdanoff, Charles Brondos, Richard Brooks, Jose Canedo, Ira Casson, Niranjan Chandragiri, John Chawluk, Shahid Choudhary, Nelson Cooke, Lizbeth Cravens, Michael Daras, Lloyd Davis, Konstantin Dzamashvili, Roy Elterman, Philip Ente, Raina Ernstoff, Toufic Fakhoury, Jose Ferreira, Robert Frere, Steven Gable, Bruno Gallo, John Gambin, Peter Gannon, Daniel Garber, Bogdan Gheorghiu, John Gilroy, Paul Ginsburg, Stanley Ginsburg, Justin Graff, Joel Grenberg, Scott Hall, Mark Harris, Rizwan Hassan, Nancy Hausman, Barry Hendin, Andrew Hilburger, Sandra Horowitz, Phillip Hsu, Charles Imbus, Riaz Janjua, Linda Johnson, Jeffrey Jones, Raymond Kandt, Avery Katz, Stephen Kirzinger, Daniel Lee, Richard Leschek, Thomas Lin, Jan Mashman, Paul Mazzeo, Paul Maccabe, James Mcdowell, David Mclaren, Laszlo Mechtler, Elliot Michel, Marshall Nash, Steven Norris, Steven Novom, Burtram Odenheimer, Victor Owusu-Yaw, Luis Pagani, Carol Pappas, Steven Park, Mrugendra Patel, Jordan Popper, Arun Rajan, David Rankine, Sumant Rawat, Mary River, David Roby, David Rosenbaum, Jonathan Ross, Harmeet Sachdev, Micheal Sauter, Jack Scariano, Arthur Schiff, Peter Schilder, Kenneth Siegel

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Introduction: The tolerability of lamotrigine as adjunctive and monotherapy in patients requiring a change in antiepileptic drug (AED) therapy was assessed in this multicenter, open-label study. Open-label studies conducted in the clinic setting may provide additional drug tolerability and effectiveness information that may not be evident in pre-approval clinical trials. Methods: Adult patients with partial seizures received adjunctive lamotrigine for 16 weeks. Patients taking a single enzyme-inducing AED could convert to lamotrigine monotherapy for an additional 12 weeks. Patients were assessed at baseline, end of adjunctive therapy, and end of monotherapy using the Liverpool Adverse Experience Profile (AEP), Quality of Life in Epilepsy-31, a patient satisfaction rating, and a subjective investigator global assessment. Results: Of the 547 patients enrolled (mean age 42.7 years, 58% female), 421 (77%) completed adjunctive therapy. Upon completion of the adjunctive phase, mean improvement from baseline was 4.3 points on the AEP, and investigators rated 71% of patients as improved in global status. Overall score on the QOLIE 31 improved by 10 points from baseline. One hundred and seventy-eight patients entered and 143 (80%) patients completed the monotherapy phase. In patients completing lamotrigine monotherapy, mean improvement from baseline was 5.9 points on the AEP, and investigators rated 92% as improved in global status. Overall score on the QOLIE 31 score improved by 15 points from baseline. Conclusion: Lamotrigine as adjunctive treatment and monotherapy may improve side effect burden and quality of life in patients requiring a change in AED therapy.

Original languageEnglish (US)
Pages (from-to)254-261
Number of pages8
Issue number4
StatePublished - Jun 2005
Externally publishedYes


  • Adjunctive therapy
  • Epilepsy
  • Lamotrigine
  • Monotherapy
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Psychology(all)


Dive into the research topics of 'Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen'. Together they form a unique fingerprint.

Cite this